CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Jazz Pharmaceuticals plc (JAZZ) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Jazz Pharmaceuticals plc (JAZZ)

Pharmaceutical Preparations · market cap $15.3B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-17
Conference
Pipeline
20
programs
Upcoming events
6
next 90d+
Dossier
Ready
cached
Jazz Pharmaceuticals plc is a Dublin-headquartered biopharma (founded 2003 in California, formed via the Jazz/Azur Pharma merger) focused on oncology and neuroscience. Our data shows a commercial-scale company, with $4,268M of 2025 revenue and a $13.4B market cap at ~$205.7. It also shows a broad, multi-phase pipeline and a cluster of estimated-date readouts from December 2026 to mid-2027.
The catalyst path
  • 2026-11-17Conferenceimp 3/10
  • 2026-12-15 (est.)Phase 2 · CPX-351imp 7/10
  • 2026-12-24 (est.)Phase 2 · Defibrotideimp 7/10
  • 2026-12-31 (est.)Phase 2 · Zanidatamabimp 7/10
  • 2027-04-16PDUFA · Cannabidiolimp 8/10
  • 2027-06-15 (est.)Phase 3 · CPX-351imp 9/10
Pipeline
AssetPhaseIndication
SativexPhase 3Multiple Sclerosis
NabiximolsPhase 3Pain
SuvecaltamidePhase 2Parkinson Disease
Sativex®Phase 3Spasticity
GWP42003-PPhase 3Epilepsy
XyremPhase 3Narcolepsy With Cataplexy
LurbinectedinPhase 2Refractory Ewing Sarcoma
GWP42006Phase 2Epilepsy
ZW25 (Zanidatamab)Phase 2HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Recombinant Granulocyte Colony-Stimulating FactorPhase 2Acute Myeloid Leukemia
GWP42003Phase 2Schizophrenia
EvorpaceptPhase 2HER2-expressing Cancers
JZP-110Phase 3Obstructive Sleep Apnea
BrincidofovirPhase 3Adenovirus Infection
GWP42004Phase 2Dyslipidemias
Xyrem®Phase 3Fibromyalgia
JZP385Phase 2Essential Tremor
Dordaviprone (ONC201)Phase 3H3 K27M
Sodium OxybatePhase 3Essential Tremor
IM JZP-458Phase 3Acute Lymphoblastic Leukemia
Price & technical context
3-month
-3.6%
6-month
+6.3%
12-month
+72.2%
52-wk range
$141.07–$261.62
vs 50-day MA
+6.5%
vs 200-day MA
+10.7%
Realized vol
37.3%
Max drawdown
-32.2%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for JAZZ (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.